查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1456967

全球整容手术市场 - 2024 年至 2029 年预测

Global Cosmetic Surgery Market - Forecasts from 2024 to 2029
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 136 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

整容手术市场预计将从2022年的482.4亿美元成长到2029年的896.71亿美元，复合年增长率为9.26%。

整容手术是一种利用手术和非手术方法来改善外观的医疗手术。整容手术，也称为整容手术，是整形手术的一部分，旨在透过外科手术和医疗程序来改善一个人的外表。整容手术是选择性的，重点是改善美观、对称性和比例。整容手术有多种类型，包括脸部、身体、乳房和活肤。接受整容手术的原因包括增强、矫正和逆转老化。一个人可以接受整容手术来减少、强调、提升或增强身体特征。多年来，由于手术技术的改进、富裕程度的提高、都市化的加速、全球化的文化影响以及受过专业培训的医生数量的增加，对整容手术的需求显着增加。

市场驱动因素：

  • 由于旨在吸引顾客进行美容护理的许可医疗水疗中心的增加，预计该市场将会成长。

接受手术和非手术整容手术的患者数量不断增加，导緻美容医学行业在世界范围内不断发展，并不断扩大和发展。由于此因素，各国获得美国批准或许可的医疗食品药物管理局数量显着增加。提供多种服务的医疗水疗中心的激增带来了激烈的价格竞争，进一步压低了美容护理的价格。

  • 技术先进产品的便利性预计将推动全球整容手术的需求。

市场上领先的产品和设备製造商正致力于提高盈利并努力加强其当前的市场占有率。由于对副作用较小和术后干预的先进产品的需求不断增加，市场相关人员正在专注于研发以引入先进产品。

按地区

按地区划分，整容手术市场分为北美、南美、欧洲、中东和非洲以及亚太地区。最大的整容手术市场是美国，其次是欧洲。此外，亚太地区预计将拥有最快的市场成长。促成这一增长的因素包括熟练的外科医生的可用性、医疗保健成本的上升、新兴经济体技术溢出的增加以及外科手术意识的提高。

主要进展

  • 2023 年 2 月，Candela 宣布推出 FDA 核准的 Profound Matrix 系统。该系统旨在纠正、维护和恢復各个衰老阶段的皮肤。该系统包括 Sublime、Sublative RF 和 Matrix Pro施用器。 Sublime 和 Sublative RF 可以改善细纹，而 Matrix Pro 可以再生和建构胶原蛋白，从而改善皮肤的整体外观和纹理。
  • 2022 年 6 月：总部位于伦敦的全球美容公司 Sinclair 宣布重大品牌重塑。该公司在其已经令人印象深刻的注射剂组合中添加了补充药物，包括 MaiLi 的最新 HA 技术和注射型胶原蛋白刺激剂 Lanluma。新的 EBD 业务描述了各种基于能源的解决方案。辛克莱不断增长的投资组合、辛克莱学院的教育计画以及全球影响力反映了其新的身份确认。该品牌已转型为现代、充满活力和优质的品牌，同时仍保持其优雅气质。
  • 2022 年 3 月：硅胶乳房植入製造商 Sientra 20 年来首次获得加拿大卫生署的核准。 Clarion Medical Technologies 的高强度黏性硅胶乳房植入有临床资料支持，并具有无与伦比的安全性。 Sienta 是加拿大唯一仅供经过委员会认证的整形外科医生使用的乳房植入品牌。该公司透过当地合作伙伴 Kai Aesthetic 在加拿大提供植入，确保高品质、安全和服务标准。

提供的产品

  • truSculpt(R) flex：Cutera 的 truSculpt(R) flex 基于原始 MDS（多向刺激），这是一种直接刺激肌肉的全新技术，可提供有保证且可靠的结果。 MDS 采用生物电脉衝，可有效增强、塑形和调理大腿、臀部和腹部。 truSculpt Flex 的腹部、臀部和大腿同时受到八个不同肌肉群的刺激。 truSculpt Flex 比其他塑身设备覆盖更多的治疗空间。运动计画包括间歇训练、肌力训练和体能训练。 truSculpt 弯曲运动比标准的健身房活动强度更大。
  • Lumenis M22TM模组化美容雷射多用途平台：称为M22TM的模组化多用途平台用于治疗30多种皮肤病和除毛。 M22TM 被世界各地的医生使用，能够为各种患者和病症提供有效的治疗。 M22TM 可以将四种不同的技术整合到一个模组化系统中。 M22TM 通用 IPL 和 AOPT 的组合为高级用户提供了完全控制，并允许他们轻鬆地为每个患者和每种情况自订参数。 Lumenis 还拥有采用 Golden Line 设计的优质 M22 版本，可为美容医学领域提供准确、安全且非常成功的光和雷射治疗。

目录

第一章 简介

  • 市场概况
  • 市场定义
  • 调查范围
  • 市场区隔
  • 货币
  • 先决条件
  • 基准年和预测年时间表
  • 相关人员的主要利益

第二章调查方法

  • 研究设计
  • 调查过程

第三章执行摘要

  • 主要发现
  • CXO观点

第四章市场动态

  • 市场驱动因素
  • 市场限制因素
  • 波特五力分析
  • 产业价值链分析
  • 分析师观点

第五章全球整容手术市场：按类型

  • 介绍
  • 手术过程
  • 非手术治疗
  • 抽脂手术

第六章全球整容手术市场：依身体区域划分

  • 介绍
  • 脸和胸部
  • 胸部
  • 身体和四肢

第七章全球整容手术市场：按地区

  • 介绍
  • 北美洲
  • 南美洲
  • 欧洲
  • 中东/非洲
  • 亚太地区

第八章竞争环境及分析

  • 主要企业及策略分析
  • 市场占有率分析
  • 合併、收购、协议和合作
  • 竞争对手仪表板

第九章 公司简介

  • Candela Corporation
  • Allergan
  • Merz Pharma
  • Mentor Worldwide LLC
  • Lumenis
  • Sinclair Pharma
  • Cutera
简介目录
Product Code: KSI061611460

The cosmetic surgery market is anticipated to increase from US$48.24 billion in 2022 to US$89.671 billion in 2029 at a CAGR of 9.26%.

Cosmetic surgery is a type of medical operation that uses both surgical and non-surgical methods to improve looks. Cosmetic surgery, also known as aesthetic surgery, is a branch of plastic surgery that aims to enhance a person's appearance through surgical and medical techniques. It is elective and focuses on improving aesthetic appeal, symmetry, and proportion. There are various types of cosmetic surgery, including facial procedures, body contouring, breast procedures, and skin rejuvenation. Reasons for cosmetic surgery include enhancement, correction, and aging reversal. A person may have cosmetic surgery done to reduce, accentuate, lift, or enhance a physical portion. Over the years, the demand for cosmetic surgery has grown significantly, spurred by improvements in surgical techniques, rising affluence, accelerating urbanization, the cultural effects of globalization, and an increase in doctors with specialized training.

MARKET DRIVERS:

  • An increase in licensed medical spas to draw clientele for cosmetic procedures is anticipated in the growth of the market.

An expansive and appealing aesthetic medicine industry is now operating worldwide because of the rise in the number of patients undergoing surgical and non-surgical cosmetic procedures. The number of medical spas that have FDA approval and licensing has greatly expanded as a result of this factor in many various countries. Intense pricing competition brought on by the proliferation of medical spas offering a wide range of services has driven down the price of cosmetic procedures even more.

  • Technology-advanced product accessibility is expected to drive the demand for cosmetic procedures globally

Leading producers of goods and devices on the market noted the profitable expansion and are working to enhance their current market share. Due to the growing demand for advanced products with fewer side effects and post-surgical interventions, market players are focusing on R&D to introduce advanced products.

By Geography

Geographically, the cosmetic surgery market is segmented as North America, South America, Europe, the Middle East and Africa, and Asia Pacific. The biggest market for cosmetic surgery is in the United States, followed by Europe. Asia Pacific is also anticipated to have the fastest regional market growth. The availability of skilled surgeons, rising healthcare costs, increased technology spillover from developed economies, and expanding awareness of surgery are all factors contributing to this growth.

Key Developments:

  • February 2023: Candela announced the launch of the FDA-cleared Profound Matrix System, designed to correct, maintain, and restore skin at different stages of aging. The system includes the Sublime, Sublative RF, and Matrix Pro applicators. The Sublime and Sublative RF treatments improve fine line and wrinkle appearance, while the Matrix Pro applicator regenerates and builds collagen, enhancing overall skin appearance and texture.
  • June 2022: Sinclair, a London-based global aesthetics company, has announced a significant rebranding. The company has added complementary medicines to its already exceptional range of injectables, including MaiLi's latest HA technology and Lanluma, an injectable collagen stimulant. The new EBD business offers a range of energy-based solutions. Sinclair's growing portfolio, educational programs through Sinclair College, and global presence reflect its new identity. The brand has transformed into contemporary, lively, and premium while maintaining its elegance.
  • March 2022: Sientra, a silicone gel breast implant manufacturer, has been approved by Health Canada for the first time in 20 years. The High-Strength Cohesive Silicone Gel Breast Implants, distributed by Clarion Medical Technologies, are backed by clinical data and have an unrivaled safety profile. Sientra is the only brand of breast implants in Canada available exclusively from board-certified plastic surgeons. The company will offer implants in Canada through local partner Kai Aesthetic, ensuring high quality, safety, and service standards.

Product Offerings:

  • truSculpt(R) flex: Cutera's truSculpt(R) flex is based on the original Multi-Directional Stimulation (MDS), a brand-new technique for direct muscle stimulation that offers secure and reliable outcomes. MDS employs a bioelectrical impulse that has been shown via studies to give targeted muscle stimulation for the best thigh, glute, and abdominal strengthening, firming and toning results. The abdomen, buttocks, and thigh regions of truSculpt flex are simultaneously stimulated by eight different muscle groups. More treatment space is covered by truSculpt flex than by any other body sculpting device. The exercise plans include interval training, strength training, and a conditioning routine. The truSculpt flex workout is much more intense than standard gym-based activities.
  • The Lumenis M22TM Modular Aesthetic Laser Multi-Application Platform: A modular multi-application platform called M22TM is used to treat and remove hair from more than 30 different skin diseases. M22TM, which is used by doctors all over the world, enables one to effectively treat a wide range of patients and conditions. It can combine four different technologies in a Modular System. With the M22TM Universal IPL and AOPT combined, advanced users have complete control and can easily customize the parameters for each patient and each condition. Lumenis also has a premium M22 version with the golden line design that offers the aesthetic medical sector precise, secure, and successful light and laser-based therapies.

Segmentation

By Type

  • Surgical Procedures
  • Non-Surgical Procedures
  • Liposuction

By Body Part

  • Face and Head
  • Breast
  • Body and Extremities

By Geography

  • North America
  • USA
  • Mexico
  • Canada
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Others
  • Asia Pacific
  • India
  • China
  • Japan
  • South Korea
  • Taiwan
  • Thailand
  • Indonesia
  • Others

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. Market Overview
  • 1.2. Market Definition
  • 1.3. Scope of the Study
  • 1.4. Market Segmentation
  • 1.5. Currency
  • 1.6. Assumptions
  • 1.7. Base, and Forecast Years Timeline
  • 1.8. Key Benefits to the stakeholder

2. RESEARCH METHODOLOGY

  • 2.1. Research Design
  • 2.2. Research Processes

3. EXECUTIVE SUMMARY

  • 3.1. Key Findings
  • 3.2. CXO Perspective

4. MARKET DYNAMICS

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. Threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis
  • 4.5. Analyst View

5. GLOBAL COSMETIC SURGERY MARKET, BY TYPE

  • 5.1. Introduction
  • 5.2. Surgical Procedures
    • 5.2.1. Market Opportunities and Trends
    • 5.2.2. Growth Prospects
    • 5.2.3. Geographic Lucrativeness
  • 5.3. Non-Surgical Procedures
    • 5.3.1. Market Opportunities and Trends
    • 5.3.2. Growth Prospects
    • 5.3.3. Geographic Lucrativeness
  • 5.4. Liposuction
    • 5.4.1. Market Opportunities and Trends
    • 5.4.2. Growth Prospects
    • 5.4.3. Geographic Lucrativeness

6. GLOBAL COSMETIC SURGERY MARKET, BY BODY PART

  • 6.1. Introduction
  • 6.2. Face and Breast
    • 6.2.1. Market Opportunities and Trends
    • 6.2.2. Growth Prospects
    • 6.2.3. Geographic Lucrativeness
  • 6.3. Breast
    • 6.3.1. Market Opportunities and Trends
    • 6.3.2. Growth Prospects
    • 6.3.3. Geographic Lucrativeness
  • 6.4. Body and Extremities
    • 6.4.1. Market Opportunities and Trends
    • 6.4.2. Growth Prospects

Geographic Lucrativeness

7. GLOBAL COSMETIC SURGERY MARKET, BY GEOGRAPHY

  • 7.1. Introduction
  • 7.2. North America
    • 7.2.1. By Type
    • 7.2.2. By Body Part
    • 7.2.3. By Country
      • 7.2.3.1. United States
        • 7.2.3.1.1. Market Opportunities and Trends
        • 7.2.3.1.2. Growth Prospects
      • 7.2.3.2. Canada
        • 7.2.3.2.1. Market Opportunities and Trends
        • 7.2.3.2.2. Growth Prospects
      • 7.2.3.3. Mexico
        • 7.2.3.3.1. Market Opportunities and Trends
        • 7.2.3.3.2. Growth Prospects
  • 7.3. South America
    • 7.3.1. By Type
    • 7.3.2. By Body Part
    • 7.3.3. By Country
      • 7.3.3.1. Brazil
        • 7.3.3.1.1. Market Opportunities and Trends
        • 7.3.3.1.2. Growth Prospects
      • 7.3.3.2. Argentina
        • 7.3.3.2.1. Market Opportunities and Trends
        • 7.3.3.2.2. Growth Prospects
      • 7.3.3.3. Others
        • 7.3.3.3.1. Market Opportunities and Trends
        • 7.3.3.3.2. Growth Prospects
  • 7.4. Europe
    • 7.4.1. By Type
    • 7.4.2. By Body Part
    • 7.4.3. By Country
      • 7.4.3.1. United Kingdom
        • 7.4.3.1.1. Market Opportunities and Trends
        • 7.4.3.1.2. Growth Prospects
      • 7.4.3.2. Germany
        • 7.4.3.2.1. Market Opportunities and Trends
        • 7.4.3.2.2. Growth Prospects
      • 7.4.3.3. France
        • 7.4.3.3.1. Market Opportunities and Trends
        • 7.4.3.3.2. Growth Prospects
      • 7.4.3.4. Italy
        • 7.4.3.4.1. Market Opportunities and Trends
        • 7.4.3.4.2. Growth Prospects
      • 7.4.3.5. Spain
        • 7.4.3.5.1. Market Opportunities and Trends
        • 7.4.3.5.2. Growth Prospects
      • 7.4.3.6. Others
        • 7.4.3.6.1. Market Opportunities and Trends
        • 7.4.3.6.2. Growth Prospects
  • 7.5. Middle East and Africa
    • 7.5.1. By Type
    • 7.5.2. By Body Part
    • 7.5.3. By Country
      • 7.5.3.1. Saudi Arabia
        • 7.5.3.1.1. Market Opportunities and Trends
        • 7.5.3.1.2. Growth Prospects
      • 7.5.3.2. UAE
        • 7.5.3.2.1. Market Opportunities and Trends
        • 7.5.3.2.2. Growth Prospects
      • 7.5.3.3. Others
        • 7.5.3.3.1. Market Opportunities and Trends
        • 7.5.3.3.2. Growth Prospects
  • 7.6. Asia Pacific
    • 7.6.1. By Type
    • 7.6.2. By Body Part
    • 7.6.3. By Country
      • 7.6.3.1. Japan
        • 7.6.3.1.1. Market Opportunities and Trends
        • 7.6.3.1.2. Growth Prospects
      • 7.6.3.2. China
        • 7.6.3.2.1. Market Opportunities and Trends
        • 7.6.3.2.2. Growth Prospects
      • 7.6.3.3. India
        • 7.6.3.3.1. Market Opportunities and Trends
        • 7.6.3.3.2. Growth Prospects
      • 7.6.3.4. South Korea
        • 7.6.3.4.1. Market Opportunities and Trends
        • 7.6.3.4.2. Growth Prospects
      • 7.6.3.5. Taiwan
        • 7.6.3.5.1. Market Opportunities and Trends
        • 7.6.3.5.2. Growth Prospects
      • 7.6.3.6. Thailand
        • 7.6.3.6.1. Market Opportunities and Trends
        • 7.6.3.6.2. Growth Prospects
      • 7.6.3.7. Indonesia
        • 7.6.3.7.1. Market Opportunities and Trends
        • 7.6.3.7.2. Growth Prospects
      • 7.6.3.8. Others
        • 7.6.3.8.1. Market Opportunities and Trends
        • 7.6.3.8.2. Growth Prospects

8. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 8.1. Major Players and Strategy Analysis
  • 8.2. Market Share Analysis
  • 8.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 8.4. Competitive Dashboard

9. COMPANY PROFILES

  • 9.1. Candela Corporation
  • 9.2. Allergan
  • 9.3. Merz Pharma
  • 9.4. Mentor Worldwide LLC
  • 9.5. Lumenis
  • 9.6. Sinclair Pharma
  • 9.7. Cutera